iCAD reports Xoft Axxent milestone
Computer-aided detection (CAD) software developer iCAD said that its Xoft Axxent...Read more on AuntMinnie.comRelated Reading: iCAD features AI software for breast imaging at RSNA iCAD features Xoft Axxent upgrades at ASTRO 2019 iCAD to highlight AI for tomosynthesis at ECR iCAD touts clinical results with Xoft Axxent brachytherapy iCAD touts study on radiation therapy savings
Intraoperative radiation therapy is an emerging option for adjuvant therapy for early stage breast cancer, although it is not currently considered standard of care in the United States. We applied time-driven activity-based costing to compare two alternative methods of breast intraoperative radiation therapy, including treatment similar to the techniques employed in the TARGIT-A clinical trial and a novel version with CT-guidance and high-dose-rate (HRD) brachytherapy.
ConclusionFive-year local control and disease-specific survival rates of patients surgically treated for vaginal non-SCC were favorable. Therefore, surgery could be a safe and reasonable option for early-stage primary vaginal non-SCC.
High dose-rate (HDR) brachytherapy is commonly administered as a boost to external beam radiation therapy (EBRT). Our purpose was to compare toxicity with increasingly hypofractionated EBRT in combination with a single 15 Gy HDR boost for men with intermediate-risk prostate cancer.
Conclusions: The AIRO vision implies that specific strategic interventions must be carried out in the field of national guidelines, education, research, and communication with patients and colleagues of other specialties in an interdisciplinary setting. PMID: 32190074 [PubMed]
Conclusions: The first interstitial and surface HDR brachytherapy for cutaneous squamous cell carcinoma of a finger interspace for hand function preservation is presented. The initial experience revealed that brachytherapy was tolerated but with notable acute and late side effects. Treatment did result in tumor shrinkage with organ preservation and function of two rays. A larger cohort of patients will be required for additional conclusions related to long-term clinical benefits in patients who refuse ray amputation. PMID: 32190070 [PubMed]
AbstractThe incidence of neuroendocrine tumours (NETs) is increasing, but curative therapeutic options are limited because diagnosis is often delayed until the tumour has metastasized. Peptide receptor radionuclide therapy (PRRT) is among the most effective therapeutic options for metastatic NETs because of targeted delivery of radioactivity to the tumour via the somatostatin receptor (SSTR) and relatively low systemic toxicity. However, current PRRT regimes result in palliation rather than cure, and higher doses of PRRT that might achieve remission would also be too toxic to the patients. Therefore, there is a need to imp...
AbstractIntroductionThe aim of this study is to determine whether99mTc-MAA SPECT/CT-based dosimetry could predict the actual absorbed dose in hepatocellular carcinoma (HCC) or liver metastases, treated by glass or resin microspheres.Material and methodsFifty-seven patients who underwent selective internal radiation therapy (SIRT) were retrospectively included in the study, for a total of 59 treatments. Nineteen HCC were treated by resin microspheres (HCC-SIR), 20 HCC with glass microspheres (HCC-Thera), and 20 liver metastases with resin microspheres (Metastases-SIR). The mean absorbed doses in tumoral liver (Dm) and non-t...
The impending implementation of the Radiation Oncology Alternative Payment Model (APM) is poised to initiate dramatic disruption in the financial incentives associated with radiation oncology practice, reversing previous incentives for increased fractionation and moving toward incentivizing brevity of care.1 Such incentivization theoretically favors treatment modalities such as hypofractionation and stereotactic body radiation therapy over traditional external beam radiation therapy (EBRT), provided they can yield comparable outcomes to EBRT.
Radical radiation therapy in oropharyngeal malignancies have a significant toxicity especially in relation to dose to dysphagia aspiration related structures (DARS), mucositis and aspiration which leads to prolonged overall treatment times, thereby, having an impact on survival outcomes. Interstitial Brachytherapy (ISBT) has significant role in reducing these toxicities, however, literature comparing Intensity modulated radiation therapy (IMRT) with Brachytherapy boost is lacking. Our study looks in to the clinical outcomes and toxicity profile while comparing the two treatment modalities.
Abstract Brachytherapy is an invasive therapy with placement of radiation source into or near the tumor. The difference between planning target volume and clinical target volume is minimal, and the dose out of the tumor reduces rapidly due to the inverse-square law. High-dose-rate brachytherapy enables three-dimensional image guidance, and currently, tumor dose as well as doses of the surrounding normal structures can be evaluated accurately. High-dose-rate brachytherapy is the utmost precision radiation therapy even surpassing carbon ion therapy. Biological disadvantages of high-dose rate have been overcome by th...